Teligent — IGI — Shareholder Meeting (May 2008)
18 slides from Teligent's shareholder meeting presentation, May 12, 2008
Slide 1: Presentation to Shareholders
IGI. Laboratories Inc. Presentation to Shareholders May 7, 2008
Slide 2: Annual Meeting of Stockholders Agenda
OO IGI Laboratories Inc. Annual Meeting of Stockholders Agenda + Call to Order + Introductions + Designation of Inspector of Election, Proof of Mailing Meeting Notice, Report on Presence of a Quorum. + Proposal 1: Election of Terence O7Donnell, Stephen J. Mortis, Rajiv ‘Mathur and Jane E. Hager to s
Slide 3: Highlights of First Quarter 2008
OE —— IGI, Laboratories Inc. Highlights of First Quarter 2008 + Revenues increased 83% to $1,500,000 over same period last year * Net income increased 110° to $40,000 compared to a loss of $410,00 during the same period last year * Second consecutive quarter of Operating Profit from continuing opera
Slide 4: OI
OI IGI, Laboratories Inc.
Slide 5: Net Income
ee IGI, Laboratories Inc. Net Income et Loe
Slide 6: Product Life Cycles
ee IGI, Laboratories Inc. Product Life Cycles 1200 1000 0 % 00 “0 ™ Cometic 1 — Cosmetic 2 ° Cosmetic 3 + 2 8 «© 8 6 7 8 8 —Ceamati 4 rama Years
Slide 7: Seasonality of sales
__§_<_ IGI Laboratories Inc. ‘Seasonality of sales 1400 200 1000 3 e0 g 8 oo ‘00 20 © ‘Cosmete Pract 1 2 3 4 an ‘uaner pos
Slide 8: The Multi Billion $ Market
Oe IGI Laboratories Inc. The Multi Billion § Market According to the American Academy of Dermatology, approximately 80% of Americans will be affected by some kind of skin condition in their lifetime. The skin care market internationally is approximately $10 bi Retail skin care products $8.1 billion
Slide 9: The Multi Billion $ Market
OLE IGI Laboratories Inc. The Multi Billion § Market *Revenue Examples by Type of Product: Acne: The US prescription acne market is estimated at $1.3 billion in 05, DIFFERIN®(Adapalene) - Galderma US in ‘06 = $170 million (patent ends 2010) Anti-Aging: Over $5.0 billion forecast by 2011 (anti-aging
Slide 10: The Multi Billion $ Market
IGT, Laboratories Inc. The Multi Billion § Market *Occurrence Rates DERMATITIS i BM eczema | FUNGAL 5 1 in 18 oF INFECTIONS | 7 15 million | 1in 6, or PSORIASIS. nao *Navigant Consulting Ine lorama Information
Slide 11: IGI Laboratories Objectives
IGT, Laboratories Inc. IGI Laboratories Objectives + Demonstrate how the products we manufacture are unique and superior + Determine how our technology and manufacturing will fit into our customer's product lines * Provide top quality products and services ee
Slide 12: Quality Management System
OL IGI, Laboratories Inc. Quality Management System Javaity Unit ‘ual ssares uty Corel Devan podvalsoion
Slide 13: Therapeutic Categories of Products Currently Manufactured
OE IGI, Laboratories Inc. Therapeutic Categories of Products Currently Manufactured + Keratolyties * Anesthetic * Anti-fungal * Anti-inflammatory * Anti-prurities * Local Analgesies ee
Slide 14: IGI's Dermatology Pipeline
ee IGI, Laboratories Inc. IGI’s Dermatology Pipeline * Psoriasis + Adult Rosacea * Basil Cell Carcinoma * Genital Warts + Acne: + Ichthyosis * Other: Sunscreens, Topical Analgesic and Anesthetic, Ant ae Inflammatory.
Slide 15: Business Model
OIL IGI Laboratories Inc. Business Model + Collaborate with dermatology & cosmetie partners in development + Provide formulation development, stability in-vitro and pre-clinical animal studies for scale-up and commercialization. + Provide support for Drug Master File (DMF) preparation, toxicity test
Slide 16: IGI's future is bright with the potential for a strong coiled spring effect
Laboratories Inc. IGH’s future is bright with the potential for a strong “coiled spring” effect uU Expenses ~~ —_ Management + Strong, diversified pipeline into 2008 & 2009 + Current expense base will not increase relative to sales + Raised near-term funding for operating needs + No material unsecur
Slide 17: Mar08
Mar08 Sep07, Novo? Jul07 2.5 2.0 15 1.0 05
Slide 18: IGI Laboratories Inc.
IGI. Laboratories Inc.